Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 14, 2025 14:30 ET | Source: Kyverna Therapeutics, Inc.

Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

EMERYVILLE, Calif., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with...
November 12, 2025 16:05 ET | Source: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Topline data from registrational trial in stiff person syndrome (SPS) now expected in early 2026; narrowed from previous guidance of first half 2026; BLA submission anticipated in 1H 2026 Positive...
November 10, 2025 08:00 ET | Source: Kyverna Therapeutics, Inc.

Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

EMERYVILLE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients...
November 03, 2025 08:00 ET | Source: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance

Initial funding of $25 million from the first of four tranches Facility strengthens Kyverna’s financial flexibility, further supporting advancement of its late-stage indications in generalized...
October 29, 2025 06:30 ET | Source: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company’s registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically...
October 25, 2025 11:00 ET | Source: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA) KYV-101 continues to...
October 22, 2025 08:00 ET | Source: Kyverna Therapeutics, Inc.

Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis

EMERYVILLE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with...
September 24, 2025 09:05 ET | Source: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved expanded disability status scale scores (EDSS) ...
September 15, 2025 13:02 ET | Source: Kyverna Therapeutics, Inc.

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

Oral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow up Enrollment for registrational Phase 3 portion of KYSA-6 trial in MG on track to initiate...
August 28, 2025 08:00 ET | Source: Kyverna Therapeutics, Inc.

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

KYV-101 has the potential to deliver durable, drug-free, disease-free remission in myasthenia gravis and set a new treatment standard for stiff person syndrome Innovative FDA-aligned KYSA-6 Phase 3...